Much of the funding that Canada has provided to the COVAX facility is for the procurement of vaccines by COVAX. COVAX purchases the vaccines and allocates them through the WHO allocation mechanism to countries in need.
As such, the 87 million doses that we have procured the equivalent of is based on a calculation used by all G7 countries to determine the equivalent dose volume that their financial contribution would provide. Therefore, Canada is calculating both the in-kind surplus doses provided to COVAX for allocation, as well as the equivalent, the number of doses that COVAX will be able to procure directly from manufacturers through the financial support provided.